skip to content »

Center for Cell and Gene Therapy

Houston, Texas

Center for Cell and Gene Therapy
Center for Cell and Gene Therapy
not shown on screen

Myeloma

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H (HIMSUM): This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.

H23574; Phase I Study of Adoptive Transfer of Autologous T-lymphocytes Engrafted with a Chimeric Antigen Receptor Targeting the Kappa Light Chain of Immunoglobin Expressed in Patients with Chronic Lympocytic Leukemia or B-cell Lymphoma (CHARKALL): This study uses a chimeric receptor made from an antibody that recognizes the kappa light chain molecule present on non-Hodgkin lymphoma, multiple myeloma or chronic lymphocytic leukemia cancer cells that is expressed in T lymphocytes so that they become able to kill cancer cells. The CAR also contains another component called CD28 that should enable the cells to last longer in the body and therefore be more effective

H28064; A Trial of Single Autologous Transplant with or without RVD Consolidation Versus Tandem Transplant and Maintenance Therapy for Patients with Multiple Myeloma (BMT CTN 0702): This study compares three (3) different treatment approaches for multiple myeloma: 1) tandem autologous stem cell transplant and maintenance; 2) a single autologous stem cell transplant and consolidation and maintenance; 3) a single autologous stem cell transplant and maintenance. The decision of which treatment a patient will receive on this study is decided by random selection, not by the physician or patient.

E-mail this page to a friend